Last update 07 Nov 2024

Bevacizumab biosimilar(Biocon Ltd.)

Overview

Basic Info

Drug Type
Biosimilar, Monoclonal antibody
Synonyms
Abevmy, Bevacizumab biosimilar, KRABEVA
+ [3]
Target
Mechanism
VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors), Angiogenesis inhibitors
Inactive Indication-
Originator Organization
Drug Highest PhaseApproved
Regulation-
Login to view timeline

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Advanced Lung Non-Squamous Non-Small Cell Carcinoma
AU
06 Sep 2021
Breast cancer recurrent
AU
06 Sep 2021
High grade glioma
AU
06 Sep 2021
Metastatic Non-Squamous Non-Small Cell Lung Carcinoma
AU
06 Sep 2021
Platinum-Resistant Epithelial Ovarian Carcinoma
AU
06 Sep 2021
Platinum-Resistant Fallopian Tube Carcinoma
AU
06 Sep 2021
Platinum-Resistant Primary Peritoneal Carcinoma
AU
06 Sep 2021
Recurrent Lung Non-Squamous Non-Small Cell Carcinoma
AU
06 Sep 2021
Uterine Cervical Cancer
AU
06 Sep 2021
Advanced Renal Cell Carcinoma
EU
21 Apr 2021
Advanced Renal Cell Carcinoma
IS
21 Apr 2021
Advanced Renal Cell Carcinoma
LI
21 Apr 2021
Advanced Renal Cell Carcinoma
NO
21 Apr 2021
EGFR positive Non-squamous non-small cell lung cancer
EU
21 Apr 2021
EGFR positive Non-squamous non-small cell lung cancer
IS
21 Apr 2021
EGFR positive Non-squamous non-small cell lung cancer
LI
21 Apr 2021
EGFR positive Non-squamous non-small cell lung cancer
NO
21 Apr 2021
Metastatic breast cancer
EU
21 Apr 2021
Metastatic breast cancer
IS
21 Apr 2021
Metastatic breast cancer
LI
21 Apr 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
671
fpeqrjksgd(mdxvkbxcam): Risk Ratio (RR) = 0.96 (90% CI, 0.83 - 1.12)
-
01 Feb 2021
Phase 3
671
gmgpxpcgdm(acmoiefahk): ratio = 0.96 (90% CI, 0.73 - 1.36); difference = -1.6 (95% CI, -9.0 to 5.9)
Positive
17 Sep 2020
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free